Overview Dividends

(MEDP) Medpace Holdings - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US58506Q1094

Clinical Trials, Regulatory Affairs, Data Analysis, Laboratory Services

Life Sciences Tools & Services
Market Cap in USD: 16,085m
IPO / Inception: 2016-08-11
Return 12m vs S&P 500: 43.0%

EPS (Earnings per Share)

EPS (Earnings per Share) of MEDP over the last years for every Quarter: "2020-12": 1.35, "2021-03": 1.14, "2021-06": 1.06, "2021-09": 1.29, "2021-12": 1.32, "2022-03": 1.69, "2022-06": 1.46, "2022-09": 2.05, "2022-12": 2.12, "2023-03": 2.27, "2023-06": 1.93, "2023-09": 2.22, "2023-12": 2.46, "2024-03": 3.2, "2024-06": 2.75, "2024-09": 3.01, "2024-12": 3.6813, "2025-03": 3.67, "2025-06": 3.103, "2025-09": 3.86, "2025-12": 0,
EPS CAGR: -42.84%
EPS Trend: 10.0%
Last SUE: -4.00
Qual. Beats: 0

Revenue

Revenue of MEDP over the last years for every Quarter: 2020-12: 259.678, 2021-03: 259.965, 2021-06: 278.293, 2021-09: 295.567, 2021-12: 308.552, 2022-03: 330.947, 2022-06: 351.207, 2022-09: 383.744, 2022-12: 394.098, 2023-03: 434.074, 2023-06: 460.868, 2023-09: 492.499, 2023-12: 498.401, 2024-03: 511.044, 2024-06: 528.104, 2024-09: 533.317, 2024-12: 536.589, 2025-03: 558.57, 2025-06: 603.311, 2025-09: 659.903, 2025-12: null,
Rev. CAGR: 22.47%
Rev. Trend: 97.5%
Last SUE: 0.77
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 42.8%
Value at Risk 5%th 59.4%
Relative Tail Risk -15.53%
Reward TTM
Sharpe Ratio 1.04
Alpha 58.58
CAGR/Max DD 0.99
Character TTM
Hurst Exponent 0.437
Beta 0.973
Beta Downside 0.903
Drawdowns 3y
Max DD 39.38%
Mean DD 13.18%
Median DD 9.17%

Description: MEDP Medpace Holdings January 06, 2026

Medpace Holdings, Inc. (NASDAQ: MEDP) is a contract research organization (CRO) that delivers end-to-end clinical development services-from Phase I through Phase IV-for pharmaceutical, biotech, and medical-device clients across North America, Europe, and Asia. Its portfolio includes trial design, central laboratory coordination, project management, regulatory affairs, monitoring, data management, pharmacovigilance, NDA submissions, and post-marketing support, as well as specialized bio-analytical, human pharmacology, imaging, and ECG reading capabilities. Founded in 1992 and headquartered in Cincinnati, Ohio, Medpace operates within the GICS “Life Sciences Tools & Services” sub-industry.

Key recent metrics: Q4 2023 revenue rose 12% YoY to $388 million, driven by a 20% increase in biotech contracts; the company reported an adjusted EBITDA margin of 14%, reflecting operational scaling after the 2022 acquisition of a European imaging lab. Sector-wide, the global CRO market is projected to grow at a 7.5% CAGR through 2028, fueled by rising R&D intensity (average 18% of pharma revenue) and the acceleration of decentralized trial models, which Medpace has integrated into its service platform.

For a deeper quantitative assessment of Medpace’s valuation dynamics, you may find it useful to explore ValueRay’s analytical tools.

Piotroski VR‑10 (Strict, 0-10) 9.0

Net Income (433.0m TTM) > 0 and > 6% of Revenue (6% = 141.5m TTM)
FCFTA 0.40 (>2.0%) and ΔFCFTA 14.43pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue -23.18% (prev -0.42%; Δ -22.76pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.41 (>3.0%) and CFO 711.2m > Net Income 433.0m (YES >=105%, WARN >=100%)
Net Debt (-141.4m) to EBITDA (520.8m) ratio: -0.27 <= 3.0 (WARN <= 3.5)
Current Ratio 0.57 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (29.7m) change vs 12m ago -7.41% (target <= -2.0% for YES)
Gross Margin 31.11% (prev 29.69%; Δ 1.42pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 122.9% (prev 99.37%; Δ 23.56pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 64.22 (EBITDA TTM 520.8m / Interest Expense TTM 7.88m) >= 6 (WARN >= 3)

Altman Z'' -1.81

(A) -0.31 = (Total Current Assets 737.3m - Total Current Liabilities 1.28b) / Total Assets 1.75b
(B) -0.34 = Retained Earnings (Balance) -596.2m / Total Assets 1.75b
(C) 0.26 = EBIT TTM 506.3m / Avg Total Assets 1.92b
(D) -0.41 = Book Value of Equity -601.6m / Total Liabilities 1.46b
Total Rating: -1.81 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 91.36

1. Piotroski 9.0pt
2. FCF Yield 4.41%
3. FCF Margin 29.83%
4. Debt/Equity 0.49
5. Debt/Ebitda -0.27
6. ROIC - WACC (= 74.03)%
7. RoE 91.88%
8. Rev. Trend 97.50%
9. EPS Trend 10.03%

What is the price of MEDP shares?

As of January 10, 2026, the stock is trading at USD 600.02 with a total of 235,707 shares traded.
Over the past week, the price has changed by +5.08%, over one month by +9.26%, over three months by +13.00% and over the past year by +69.22%.

Is MEDP a buy, sell or hold?

Medpace Holdings has received a consensus analysts rating of 3.33. Therefor, it is recommend to hold MEDP.
  • Strong Buy: 2
  • Buy: 0
  • Hold: 10
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the MEDP price?

Issuer Target Up/Down from current
Wallstreet Target Price 541.9 -9.7%
Analysts Target Price 541.9 -9.7%
ValueRay Target Price 824.9 37.5%

MEDP Fundamental Data Overview January 05, 2026

P/E Trailing = 39.8479
P/E Forward = 35.8423
P/S = 6.8202
P/B = 54.7765
P/EG = 3.6219
Beta = 1.431
Revenue TTM = 2.36b USD
EBIT TTM = 506.3m USD
EBITDA TTM = 520.8m USD
Long Term Debt = 119.1m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 24.9m USD (from shortTermDebt, last quarter)
Debt = 144.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -141.4m USD (from netDebt column, last quarter)
Enterprise Value = 15.94b USD (16.08b + Debt 144.0m - CCE 285.4m)
Interest Coverage Ratio = 64.22 (Ebit TTM 506.3m / Interest Expense TTM 7.88m)
FCF Yield = 4.41% (FCF TTM 703.6m / Enterprise Value 15.94b)
FCF Margin = 29.83% (FCF TTM 703.6m / Revenue TTM 2.36b)
Net Margin = 18.36% (Net Income TTM 433.0m / Revenue TTM 2.36b)
Gross Margin = 31.11% ((Revenue TTM 2.36b - Cost of Revenue TTM 1.62b) / Revenue TTM)
Gross Margin QoQ = 29.84% (prev 29.84%)
Tobins Q-Ratio = 9.09 (Enterprise Value 15.94b / Total Assets 1.75b)
Interest Expense / Debt = 5.48% (Interest Expense 7.88m / Debt 144.0m)
Taxrate = 22.19% (31.7m / 142.8m)
NOPAT = 393.9m (EBIT 506.3m * (1 - 22.19%))
Current Ratio = 0.57 (Total Current Assets 737.3m / Total Current Liabilities 1.28b)
Debt / Equity = 0.49 (Debt 144.0m / totalStockholderEquity, last quarter 293.6m)
Debt / EBITDA = -0.27 (Net Debt -141.4m / EBITDA 520.8m)
Debt / FCF = -0.20 (Net Debt -141.4m / FCF TTM 703.6m)
Total Stockholder Equity = 471.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 22.57% (Net Income 433.0m / Total Assets 1.75b)
RoE = 91.88% (Net Income TTM 433.0m / Total Stockholder Equity 471.3m)
RoCE = 85.76% (EBIT 506.3m / Capital Employed (Equity 471.3m + L.T.Debt 119.1m))
RoIC = 83.58% (NOPAT 393.9m / Invested Capital 471.3m)
WACC = 9.55% (E(16.08b)/V(16.23b) * Re(9.60%) + D(144.0m)/V(16.23b) * Rd(5.48%) * (1-Tc(0.22)))
Discount Rate = 9.60% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -3.38%
[DCF Debug] Terminal Value 76.69% ; FCFF base≈636.4m ; Y1≈785.1m ; Y5≈1.34b
Fair Price DCF = 622.7 (EV 17.40b - Net Debt -141.4m = Equity 17.54b / Shares 28.2m; r=9.55% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 10.03 | EPS CAGR: -42.84% | SUE: -4.0 | # QB: 0
Revenue Correlation: 97.50 | Revenue CAGR: 22.47% | SUE: 0.77 | # QB: 0
EPS next Quarter (2026-03-31): EPS=3.48 | Chg30d=+0.091 | Revisions Net=+1 | Analysts=2
EPS next Year (2026-12-31): EPS=16.51 | Chg30d=+0.024 | Revisions Net=+1 | Growth EPS=+9.2% | Growth Revenue=+12.0%

Additional Sources for MEDP Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle